A review of the biological role of miRNAs in prostate cancer suppression and progression

Doghish, Ahmed S.; Ismail, Ahmed; El-Mahdy, Hesham A.; El‐Kady, M. A.; Elrebehy, Mahmoud A.; Sallam, Al-Aliaa M.

doi:10.1016/j.ijbiomac.2021.12.141

Cited by 83 publications

(13 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, PSA alone as a biomarker still exhibits remarkable restrictions in the diagnosis and prognoses of PCa. Due to insufficient special symptoms of PCa in the early phase, it is easily confused with benign prostatauxe [ 4 , 5 ]. When evident symptoms occur, the cancers are usually in the middle and advanced phases, even with metastases [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer

Song

Peng

Luo

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Prostate cancer (PCa) is recognized as a common malignancy in male patients. The homeobox A cluster (HOXA) family members have been confirmed to be implicated in the development of several types of tumors. However, the expression pattern and prognostic values of HOXA genes in PCa have not been investigated. In this study, we analyzed TCGA datasets and identified six HOXA family members which showed a dysregulated expression in PCa specimens compared with nontumor specimens. We also explored the potential mechanisms involved in the dysregulation of HOXA family members in PCa, and the results of Pearson’s correlation revealed that most HOXA members were negatively related to the methylation degree. Moreover, we explored the prognostic values of HOXA family members and identified six survival-related HOXA members. Importantly, HOXA2, HOXA9, and HOXA10 were identified as critical PCa-related genes which were abnormally expressed in PCa and associated with clinical outcomes of PCa patients. Then, we explored the association between the above three genes and immune cell infiltration. We observed that the levels of HOXA2, HOXA9, and HOXA10 were associated with the levels of immune infiltration of several kinds of immune cells. Overall, our findings identified the potential values of the HOXA family for outcome prediction in PCa, which might facilitate personalized counselling and treatment in PCa.

show abstract

Section: Introductionmentioning

confidence: 99%

Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer

Song

Peng

Luo

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…As a type of noncoding RNA, miRNAs participate in a variety of cellular biological processes and can combine with the 3ʹUTR and regulate the expression of target genes [50,51]. It is acknowledged that the controlled expression of miRNAs is indispensable for normal cells, while the aberrant expression of miRNAs may lead to diseases, including cancers [52,53]. As reported, miR-432-5p could be regarded as a tumor inhibitor in human cancers; for example, DRAIC could promote the growth of breast cancer by sponging miR-432-5p to upregulate SLBP [54], circ-ZNF609 could target miR-432-5p to regulate the expression of LRRC1 to promote cholangiocarcinoma [55], and LINC01783 could facilitate cell proliferation, migration and invasion in non-small cell lung cancer by targeting miR-432-5p [56].…”

Section: Discussionmentioning

confidence: 99%

Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis

Wang

Yang

et al. 2022

Cell Death Dis

View full text Add to dashboard Cite

Numerous studies have shown that circRNAs are aberrantly expressed in various cancers and play a significant role in tumor progression. However, the molecular mechanisms of circRNAs in triple-negative breast cancer (TNBC) remain ambiguous. By intersecting throughput data and qRT-PCR results from tissues and cell lines, circ-TRIO was identified as a potential oncogenic regulator of TNBC. Moreover, circ-TRIO expression was detected in TNBC tissues and was correlated with the recurrence and prognosis of TNBC patients. The circular characteristics of circ-TRIO were verified by RNase R and CHX assays. Functionally, the knockdown of circ-TRIO inhibited the proliferation, migration and invasion of TNBC cells, while the overexpression of circ-TRIO resulted in the opposite impacts. Mechanistically, a dual luciferase reporter assay and RNA immunoprecipitation were performed and indicated that circ-TRIO could combine with miR-432-5p to regulate the expression of coiled-coil domain containing 58 (CCDC58). In summary, our study illustrates that circ-TRIO plays an important role in the progression of TNBC by regulating the miR-432-5p/CCDC58 axis, which could broaden our insight into the underlying mechanisms and provide a novel prognostic marker of TNBC in the clinic.

show abstract

“…But these studies differ from each other in sample type, study design, statistical measures, and systems biology methods used. Moreover, the data on the role of miRNAs in regulating gene expression changes in prostate cancer tissues is sparce ( Doghish et al, 2021 ) ( Gordanpour et al, 2012 ) ( Watahiki et al, 2011 ). Therefore, this new study design combined the publicly available expression datasets from different prostate tissues and across different microarray platforms to precisely map the interactions of key genes and miRNA involved in prostate tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers

et al. 2022

View full text Add to dashboard Cite

Background: Prostate cancer (PC) is a fatally aggressive urogenital cancer killing millions of men, globally. Thus, this study aims to identify key miRNAs, target genes, and drug targets associated with prostate cancer metastasis.Methods: The miRNA and mRNA expression datasets of 148 prostate tissue biopsies (39 tumours and 109 normal tissues), were analysed by differential gene expression analysis, protein interactome mapping, biological pathway analysis, miRNA-mRNA networking, drug target analysis, and survival curve analysis.Results: The dysregulated expression of 53 miRNAs and their 250 target genes involved in Hedgehog, ErbB, and cAMP signalling pathways connected to cell growth, migration, and proliferation of prostate cancer cells was detected. The subsequent miRNA-mRNA network and expression status analysis have helped us in narrowing down their number to 3 hub miRNAs (hsa-miR-455-3p, hsa-miR-548c-3p, and hsa-miR-582-5p) and 9 hub genes (NFIB, DICER1, GSK3B, DCAF7, FGFR1OP, ABHD2, NACC2, NR3C1, and FGF2). Further investigations with different systems biology methods have prioritized NR3C1, ABHD2, and GSK3B as potential genes involved in prostate cancer metastasis owing to their high mutation load and expression status. Interestingly, down regulation of NR3C1 seems to improve the prostate cancer patient survival rate beyond 150 months. The NR3C1, ABHD2, and GSK3B genes are predicted to be targeted by hsa-miR-582-5p, besides some antibodies, PROTACs and inhibitory molecules.Conclusion: This study identified key miRNAs (miR-548c-3p and miR-582-5p) and target genes (NR3C1, ABHD2, and GSK3B) as potential biomarkers for metastatic prostate cancers from large-scale gene expression data using systems biology approaches.

show abstract

A review of the biological role of miRNAs in prostate cancer suppression and progression

Cited by 83 publications

References 188 publications

Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer

Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer

Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis

A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers

Contact Info

Product

Resources

About